Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2010

01-01-2010 | Research Article

COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer

Authors: Johanna Mrena, Jan-Patrik Wiksten, Arto Kokkola, Stig Nordling, Ari Ristimäki, Caj Haglund

Published in: Tumor Biology | Issue 1/2010

Login to get access

Abstract

Cyclooxygenase-2 (COX-2) is an important factor in gastric carcinogenesis, and COX-2 expression in gastric cancer patients correlates with prognosis. We have now studied the impact of COX-2 in comparison to six other tissue tumor markers, DNA index, and S-phase fraction (SPF) in a large series of gastric cancer specimens. From 342 consecutive patients, 337 archival tissue specimens were available for immunohistochemistry of COX-2, HuR, cyclin A, MMP-2, p53, p21, and Ki-67 and 313 for analysis of DNA index and S-phase fraction by flow cytometry. Associations between factors were assessed by chi-square test and survival analysis by the Kaplan–Meier method and Cox model. A significant association emerged between of COX-2 and p53 (p < 0.0001), Ki-67 (p = 0.013), DNA ploidy (p < 0.0001), and SPF (p < 0.0001). In an extended multivariate analysis, COX-2 and p53 expression were independent prognostic factors for poor survival, in addition to high stage and non-curative surgery. In gastric cancer, COX-2 expression associated with markers for apoptosis and proliferation, and furthermore, it was confirmed that COX-2 and p53 are strong prognostic indicators.
Literature
1.
Kountouras J, Zavos C, Chatzopoulos D. Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol. 2005;90(4):249–59.CrossRefPubMed
2.
3.
4.
Oshima H, Oshima M, Inaba K, Taketo MM. Hyperplastic gastric tumors induced by activated macrophages in COX-2/mPGES-1 transgenic mice. EMBO J. 2004;23:1669–78.CrossRefPubMed
5.
Saukkonen K, Tomasetto C, Narko K, Rio MC, Ristimaki A. Cyclooxygenase-2 expression and effect of celecoxib in gastric adenomas of trefoil factor 1-deficient mice. Cancer Res. 2003;63(12):3032–6.PubMed
6.
Lim HY, Joo HJ, Choi JH, Yi JW, Yang MS, Cho DY, et al. Increased expression of cyclooxygenase-2 protein in human gastric carcinoma. Clin Cancer Res. 2000;6(2):519–25.PubMed
7.
Saukkonen K, Nieminen O, van Rees B, Vilkki S, Harkonen M, Juhola M, et al. Expression of cyclooxygenase-2 in dysplasia of the stomach and in intestinal-type gastric adenocarcinoma. Clin Cancer Res. 2001;7(7):1923–31.PubMed
8.
van Rees BP, Saukkonen K, Ristimaki A, Polkowski W, Tytgat GN, Drillenburg P, et al. Cyclooxygenase-2 expression during carcinogenesis in the human stomach. J Pathol. 2002;196(2):171–9.CrossRefPubMed
9.
Ristimaki A, Honkanen N, Jankala H, Sipponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997;57(7):1276–80.PubMed
10.
Saukkonen K, Rintahaka J, Sivula A, Buskens CJ, Van Rees BP, Rio MC, et al. Cyclooxygenase-2 and gastric carcinogenesis. Apmis. 2003;111(10):915–25.CrossRefPubMed
11.
Li JY, Wang XZ, Chen FL, Yu JP, Luo HS. Nimesulide inhibits proliferation via induction of apoptosis and cell cycle arrest in human gastric adenocarcinoma cell line. World J Gastroenterol. 2003;9(5):915–20.PubMed
12.
Mrena J, Wiksten JP, Thiel A, Kokkola A, Pohjola L, Lundin J, et al. Cyclooxygenase-2 is an independent prognostic factor in gastric cancer and its expression is regulated by the messenger RNA stability factor HuR. Clin Cancer Res. 2005;11(20):7362–8.CrossRefPubMed
13.
Steele RJ, Lane DP. P53 in cancer: a paradigm for modern management of cancer. Surgeon. 2005;3(3):197–205.CrossRefPubMed
14.
Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol. 2005;23(20):4499–508.CrossRefPubMed
15.
Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65(10):3980–85.CrossRefPubMed
16.
Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res. 2000;257(2):231–7.CrossRefPubMed
17.
Baba H, Korenaga D, Kakeji Y, Haraguchi M, Okamura T, Maehara Y. DNA ploidy and its clinical implications in gastric cancer. Surgery. 2002;131(1 Suppl):S63–70.CrossRefPubMed
18.
Korenaga D, Okamura T, Saito A, Baba H, Sugimachi K. DNA ploidy is closely linked to tumor invasion, lymph node metastasis, and prognosis in clinical gastric cancer. Cancer. 1988;62(2):309–13.CrossRefPubMed
19.
Victorzon M, Roberts PJ, Haglund C, von Boguslawsky K, Nordling S. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology. 1996;53(3):182–91.CrossRefPubMed
20.
Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4(7):844–7.CrossRefPubMed
21.
Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimaki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer. 2006;119(8):1897–901.CrossRefPubMed
22.
Mrena J, Wiksten JP, Nordling S, Kokkola A, Ristimaki A, Haglund C. MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer. J Clin Pathol. 2006;59(6):618–23.CrossRefPubMed
23.
Wiksten JP, Lundin J, Nordling S, Kokkola A, Haglundi C. Comparison of the prognostic value of a panel of tissue tumor markers and established clinicopathological factors in patients with gastric cancer. Anticancer Res. 2008;28(4C):2279–87.PubMed
24.
Yonemura Y, Ooyama S, Sugiyama K, Kamata T, De Aretxabala X, Kimura H, et al. Retrospective analysis of the prognostic significance of DNA ploidy patterns and S-phase fraction in gastric carcinoma. Cancer Res. 1990;50(3):509–14.PubMed
25.
Setala LP, Nordling S, Kosma VM, Lipponen PK, Eskelinen MJ, Hollmen SM, et al. Comparison of DNA ploidy and S-phase fraction with prognostic factors in gastric cancer. Anal Quant Cytol Histol. 1997;19(6):524–32.PubMed
26.
Abad M, Ciudad J, Rincon MR, Silva I, Paz-Bouza JI, Lopez A, et al. DNA aneuploidy by flow cytometry is an independent prognostic factor in gastric cancer. Anal Cell Pathol. 1998;16(4):223–31.PubMed
27.
Russo A, Bazan V, Migliavacca M, Zanna I, Tubiolo C, Tumminello FM, et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin Cancer Res. 2000;6(1):178–84.PubMed
28.
Yasa MH, Bektas A, Yukselen V, Akbulut H, Camci C, Ormeci N. DNA analysis and DNA ploidy in gastric cancer and gastric precancerous lesions. Int J Clin Pract. 2005;59(9):1029–33.CrossRefPubMed
29.
Subbaramaiah K, Altorki N, Chung WJ, Mestre JR, Sampat A, Dannenberg AJ. Inhibition of cyclooxygenase-2 gene expression by p53. J Biol Chem. 1999;274(16):10911–5.CrossRefPubMed
30.
Leung WK, To KF, Ng YP, Lee TL, Lau JY, Chan FK, et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br J Cancer. 2001;84(3):335–9.CrossRefPubMed
31.
Shun CT, Wu MS, Huang SP, Wang HP, Chuang SM, Lin JT. Cyclooxygenase-2 expression correlates with nuclear p53 accumulation in gastric carcinoma. Hepatogastroenterology. 2003;50(52):988–92.PubMed
32.
Kawabe A, Shimada Y, Uchida S, Maeda M, Yamasaki S, Kato M, et al. Expression of cyclooxygenase-2 in primary and remnant gastric carcinoma: comparing it with p53 accumulation, Helicobacter pylori infection, and vascular endothelial growth factor expression. J Surg Oncol. 2002;80(2):79–88.CrossRefPubMed
33.
Joo YE, Chung IJ, Park YK, Koh YS, Lee JH, Park CH, et al. Expression of cyclooxygenase-2, p53 and Ki-67 in gastric cancer. J Korean Med Sci. 2006;21(5):871–6.CrossRefPubMed
34.
Xu L, Zhang SM, Wang YP, Zhao FK, Wu DY, Yan X. Relationship between DNA ploidy, expression of ki-67 antigen and gastric cancer metastasis. World J Gastroenterol. 1999;5(1):10–1.PubMed
35.
Kunisaki C, Shimada H, Takahashi M, Ookubo K, Moriwaki Y, Akiyama H, et al. Prognostic factors in early gastric cancer. Hepatogastroenterology. 2001;48(37):294–8.PubMed
36.
Liu XP, Tsushimi K, Tsushimi M, Kawauchi S, Oga A, Furuya T, et al. Expression of p21(WAF1/CIP1) and p53 proteins in gastric carcinoma: its relationships with cell proliferation activity and prognosis. Cancer Lett. 2001;170(2):183–9.CrossRefPubMed
37.
Oshima CT, Iriya K, Forones NM. Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. Neoplasma. 2005;52(5):420–4.PubMed
38.
Ochiai H, Nakanishi Y, Fukasawa Y, Sato Y, Yoshimura K, Moriya Y, et al. A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases. Oncology. 2008;75(1-2):32–41.CrossRefPubMed
39.
Kim YJ, Kim MA, Im SA, Kim TM, Kim DW, Yang HK, et al. Metastasis-associated protein S100A4 and p53 predict relapse in curatively resected stage III and IV (M0) gastric cancer. Cancer Invest. 2008;26(2):152–8.CrossRefPubMed
Metadata
Title
COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer
Authors
Johanna Mrena
Jan-Patrik Wiksten
Arto Kokkola
Stig Nordling
Ari Ristimäki
Caj Haglund
Publication date
01-01-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-009-0001-4

Other articles of this Issue 1/2010

Tumor Biology 1/2010 Go to the issue

Research Article

Clinicopathologic prognostic markers of survival: an analysis of 259 patients with malignant melanoma ≥1 mm

Research Article

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer

Research Article

Estrogen prevents sustained COLO-205 human colon cancer cell growth by inducing apoptosis, decreasing c-myb protein, and decreasing transcription of the anti-apoptotic protein bcl-2

Research Article

Pro-apoptotic and antiproliferative activity of human KCNRG, a putative tumor suppressor in 13q14 region

Research Article

Laminin-derived peptide AG73 regulates migration, invasion, and protease activity of human oral squamous cell carcinoma cells through syndecan-1 and β1 integrin

Research Article

The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits